Efficacy and safety of luseogliflozin added to insulin therapy in Japanese patients with type 2 diabetes: a multicenter, 52-week, clinical study with a 16-week, double-blind period and a 36-week, open-label period

References

• Seino Y, Nanjo K, Tajima N, et al. Report of the committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Investig 2010;1:212-28
   PubMed Web of Science ®Google Scholar
• Tajima N, Noda M, Origasa H, et al. Evidence-based practice guideline for the treatment for diabetes in Japan 2013. Diabetol Int 2015;6:151-87
   Web of Science ®Google Scholar
• Stratton IM, Adler AI, Neil HAW, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2012;35:1364-79
   PubMed Web of Science ®Google Scholar
• Hajós TRS, Polonsky WH, Pouwer F, et al. Toward defining a cutoff score for elevated fear of hypoglycemia on the hypoglycemia fear survey worry subscale in patients with type 2 diabetes. Diabetes Care 2014;37:102-8
   PubMed Web of Science ®Google Scholar
• Fujita Y, Inagaki N. Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: clinical data and mechanism of action. J Diabetes Investig 2014;5:265-75
   PubMed Web of Science ®Google Scholar
• Wilding JPH, Woo V, Rohwedder K, et al. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years. Diabetes Obes Metab 2014;16:124-36
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Jelaska A, Frappin G, et al. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. Diabetes Care 2014;37:1815-23
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Jelaska A, Zeller C, et al. Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab 2015;17:936-48
   PubMed Web of Science ®Google Scholar
• Araki E, Onishi Y, Asano M, et al. Efficacy and safety of dapagliflozin over 1 year as add-on to insulin therapy in Japanese patients with type 2 diabetes: the DAISY (Dapagliflozin Added to patients under InSulin therapY) trial. Diabetes Obes Metab 2017;19:562-70
   PubMed Web of Science ®Google Scholar
• Seino Y, Sasaki T, Fukatsu A, et al. Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, phase 3 study. Curr Med Res Opin 2014;30:1245-55
   PubMed Web of Science ®Google Scholar
• Seino Y, Inagaki N, Haneda M, et al. Efficacy and safety of luseogliflozin added to various oral antidiabetic drugs in Japanese patients with type 2 diabetes mellitus. J Diabetes Investig 2015;6:443-53
   PubMed Web of Science ®Google Scholar
• Seino Y, Kaku K, Inagaki N, et al. Fifty-two-week long-term clinical study of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus inadequately controlled with diet and exercise. Endocr J 2015;62:593-603
   PubMed Web of Science ®Google Scholar
• Seino Y, Yabe D, Sasaki T, et al. Sodium-glucose cotransporter-2 inhibitor luseogliflozin added to glucagon-like peptide 1 receptor agonist liraglutide improves glycemic control with bodyweight and fat mass reductions in Japanese patients with type 2 diabetes: a 52-week, open-label, single-arm study. J Diabetes Investig 2017: published online 14 May 2017, doi:10.1111/jdi.12694
   Web of Science ®Google Scholar
• Seino Y. Luseogliflozin for the treatment of type 2 diabetes. Expert Opin Pharmacother 2014;15:2741-9
   PubMed Web of Science ®Google Scholar
• Yabe D, Hamamoto Y, Seino Y, et al. Sodium glucose co-transporter 2 inhibitor luseogliflozin in the management of type 2 diabetes: a drug safety evaluation. Expert Opin Drug Saf 2017;16:1211-18
   PubMed Web of Science ®Google Scholar
• On release of the Guideline for Clinical Evaluation of Oral Hypoglycemic Agents. Tokyo, Japan: Ministry of Health, Labour and Welfare, 2010. Available at: https://www.pmda.go.jp/files/000208194.pdf [Last accessed 20 November 2017]
   Google Scholar
• Workgroup on Hypoglycemia, American Diabetes Association. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care 2005;28:1245-9
   PubMed Web of Science ®Google Scholar
• Inagaki N, Harashima S, Maruyama N, et al. Efficacy and safety of canagliflozin in combination with insulin: a double-blind, randomized, placebo-controlled study in Japanese patients with type 2 diabetes mellitus. Cardiovasc Diabetol 2016;15:89-100
   PubMed Web of Science ®Google Scholar
• Araki E, Onishi Y, Asano M, et al. Efficacy and safety of dapagliflozin in addition to insulin therapy in Japanese patients with type 2 diabetes: results of the interim analysis of 16-week double-blind treatment period. J Diabetes Investig 2016;7:555-64
   PubMed Web of Science ®Google Scholar
• Ishihara H, Yamaguchi S, Nakano I, et al. Efficacy and safety of ipragliflozin as add-on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): a multi-centre, randomized, placebo-controlled, double-blind study. Diabetes Obes Metab 2016;18:1207-16
   PubMed Web of Science ®Google Scholar
• Terauti Y, Tamura M, Senda M, et al. Efficacy and safety of tofogliflozin in Japanese patients with type 2 diabetes mellitus with inadequate glycaemic control on insulin therapy (J-STEP/INS): results of a 16-week randomized, double-blind, placebo-controlled multicentre trial. Diabetes Obes Metab 2017;19:1397-407
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. FDA drug safety communication: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. 2015. Available at: https://www.fda.gov/downloads/Drugs/DrugSafety/UCM475487.pdf [Last accessed 20 November 2017]
   Google Scholar
• Ogawa W, Sakaguchi K. Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors. J Diabetes Investig 2016;7:135-8
   PubMed Web of Science ®Google Scholar
• Yabe D, Iwasaki M, Kuwata H, et al. Sodium–glucose co-transporter-2 inhibitor use and dietary carbohydrate intake in Japanese individuals with type 2 diabetes: a randomized, open-label, 3-arm parallel comparative, exploratory study. Diabetes Obes Metab 2017;19:739-43
   PubMed Web of Science ®Google Scholar